
PCV24 Is Clinically, Economically Unfavorable Compared with PCV21
The 24-valent pneumococcal conjugate vaccine (PCV24) was clinically and economically unfavorable for older adults when compared with currently recommended vaccine schedules in the US, including PCV20, PCV21, and PCV15 plus PPSV23. PCV21 was deemed most …